CClinicalTrials.gg
Sign In
CompletedNCT01518829Updated Oct 1, 2013

Procalcitonin in Hepatocellular Carcinoma

An observational study in Hepatocellular Carcinoma, sponsored by Ain Shams University. Completed at 1 site in Egypt. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2013-10-01.

Sponsored by Ain Shams University · Observational

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
42
Ages
18 Years to 70 Years
Sex
All
01

Study summary

the value of serum procalcitonin in differentiation between bacterial infection and non infectious inflammation in febrile HCC patients following locoeregional treatment for HCC.

02

Conditions studied

  • Hepatocellular Carcinoma

Keywords

  • hepatocellular carcinom
  • postablation syndrom
  • procalcitonin
03

In context

Carcinoma

6,741 studies on the registry are indexed under Carcinoma; 1,161 are open to participants now.

This study's enrollment of 42 is below the median of 149 across 1,175 observational studies indexed under Carcinoma.

Browse Carcinoma studies →

Lead sponsor

Ain Shams University is the lead sponsor of 1,876 studies on the registry; 423 are open to participants now.

Of its 32 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

inpatients in tropical medicine department and hepatocellular carcinoma out patient clinic ain shams university

Inclusion criteria

    • Hepatocellular carcinoma patients who will undergo TACE and/or radio-frequency.
    • Fever more than 38C after 48 hours post intervention.

Exclusion criteria

Exclusion Criteria:

  1. HCC Patients who does not develop fever after intervention.
  2. Proven infection elsewhere (e.g. UTI, chest infection..)
05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
42 participants (actual)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • Patients with hepatocellular carcinoma

    Patients with hepatocellular carcinoma who will undergo locoregional therapy

  • patients with chronic liver disease

    patients with chronic liver disease, as a control group

06

What researchers measure

Primary outcomes

  1. Differantiate between post- embolization syndrom and sepsis following locoregional treatment for hepatocellular carcinoma

    Time frame: 6months

07

Study locations

1 site
  • Tropical medicine department and hepatocellular carcinoma clinic
    Cairo, Egypt
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 1, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01518829
Lead sponsor
Ain Shams University
Responsible party
Iman Fawzy Montasser (Lecturer of Tropical medicine ,Faculty of Medicine,Ain Shams university, Ain Shams University) — Principal investigator
First posted
Jan 26, 2012
Start date
Apr 2012
Primary completion
Dec 2012
Completion
Jan 2013
Last update
Oct 1, 2013

Study contacts

Hisham K Dabbous, professor
principal investigator · Tropical medicine department

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Carcinoma→

Other studies from this sponsor

Ain Shams University

Start the discussion